Gavillet Mathilde, Rufer Nathalie, Grandoni Francesco, Carr Klappert Jeanette, Zermatten Maxime G, Cairoli Anne, Canellini Giorgia, Alberio Lorenzo, Duchosal Michel A, Spertini Olivier, Blum Sabine
Service et Laboratoire central d'Hématologie, Département d'Oncologie et Département des Laboratoires et de Pathologie, CHUV, 1011 Lausanne.
Transfusion Interrégionale CRS, Route de la Corniche 2, 1066 Epalinges.
Rev Med Suisse. 2020 Apr 29;16(N° 691-2):823-826.
The COVID-19 pandemic impacts the hematology practice. Intensive chemotherapies for high-grade lymphomas and acute leukemias, multiple myeloma treatments and most hematopoietic stem cell transplantations should be performed as usual. Low-grade lymphomas should only be treated when strictly indicated, maintenance can be postponed. Other myeloid neoplasia and their therapies cause imunosupression; dose adjustment is recommended but no brisk stopping. Sickle cell anemia patients are highly succeptible to severe COVID-19 course. Thrombocytopenia and procoagulant state are associated with severe courses of COVID-19, requiring an individualized therapy. No data indicate a risk of SARS-CoV-2 transmission through blood product transfusion.
新冠疫情对血液学实践产生影响。对于高级别淋巴瘤和急性白血病的强化化疗、多发性骨髓瘤治疗以及大多数造血干细胞移植应照常进行。低级别淋巴瘤仅在严格指征下进行治疗，维持治疗可推迟。其他髓系肿瘤及其治疗会导致免疫抑制；建议调整剂量，但不应突然停药。镰状细胞贫血患者极易感染重症新冠病毒病程。血小板减少和促凝状态与重症新冠病毒病程相关，需要个体化治疗。尚无数据表明通过输血传播新冠病毒的风险。
